AstraZeneca (AZN)
(Delayed Data from NSDQ)
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
by Zacks Equity Research
BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.
AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal
by Zacks Equity Research
At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Research Reports for Exxon Mobil, AstraZeneca & Netflix
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), AstraZeneca PLC (AZN) and Netflix, Inc. (NFLX).
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
by Zacks Equity Research
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
by Kinjel Shah
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
by Zacks Equity Research
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
AstraZeneca (AZN) Discontinues Brazikumab Development
by Zacks Equity Research
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
by Zacks Equity Research
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
by Zacks Equity Research
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
by Kinjel Shah
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
by Zacks Equity Research
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
by Zacks Equity Research
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
by Kinjel Shah
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
by Zacks Equity Research
Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.
Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
AstraZeneca (AZN) Q1 Earnings Beat, COVID Products Hurt Sales
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings while missing the same for sales. The company reaffirms its 2023 guidance.
GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook
by Zacks Equity Research
Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.